$0.51
+0.02
(+4.59%)▲
3.9%
Downside
Day's Volatility :9.22%
Upside
5.54%
21.53%
Downside
52 Weeks Volatility :99.75%
Upside
99.69%
Period | Gri Bio Inc. | Index (Russel 2000) |
---|---|---|
3 Months | -85.84% | 0.0% |
6 Months | -95.11% | 0.0% |
1 Year | -99.52% | 0.0% |
3 Years | -99.93% | -22.3% |
Market Capitalization | 1.4M |
Book Value | $5.89 |
Earnings Per Share (EPS) | 57.07 |
PE Ratio | 0.01 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -82.53% |
Return On Equity TTM | -189.06% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -8.4M |
Diluted Eps TTM | 57.07 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Sell
Neutral
Buy
Gri Bio Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Gri Bio Inc. | 11.41% | -95.11% | -99.52% | -99.93% | -99.99% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Gri Bio Inc. | 0.01 | 0.01 | NA | 0.0 | -1.89 | -0.83 | NA | 5.89 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Gri Bio Inc. | Buy | $1.4M | -99.99% | 0.01 | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Gri Bio Inc.
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 136.6%
gri is a development stage biotech company fundamentally changing the way inflammatory disease is treated. gri’s natural killer t (nkt) cell-based therapies are being developed for liver disease and acute liver failure. nkt cells share properties of both nk and t cells and are a functional link between the innate and adaptive immune responses. type 1 nkt cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. gri’s lead program, gri-0621, is an inhibitor of type i nkt cells and is being developed as a novel oral therapeutic for acute liver failure.
Organization | Gri Bio Inc. |
Employees | 4 |
CEO | Dr. W. Marc Hertz Ph.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$0.51
+4.59%
Keyarch Acquisition Corp
$0.51
+4.59%
Connexa Sports Technologies Inc
$0.51
+4.59%
Us Value Etf
$0.51
+4.59%
First Wave Biopharma Inc
$0.51
+4.59%
Global X Msci Next Emerging
$0.51
+4.59%
Fat Projects Acquisition Corp
$0.51
+4.59%
Capital Link Global Fintech
$0.51
+4.59%
Applied Uv Inc
$0.51
+4.59%